The fresh cluster in Beijing has raised fears of a resurgence of the virus in China, which had largely brought the disease under control over recent months.
Dozens of communities have been sealed off in the city to contain the spread, with residents told to avoid non-essential travel and schools closed.
Read more ›
In it, packed with dry ice, were several tiny vials. Each one held a few drops of “seed stock,” a starter kit for the production of a potential vaccine for the novel coronavirus.
The company’s job was to turn a few droplets into an amount large enough for 13,000 people — a sufficient quantity to perform large-scale trials unfolding on several continents.
“We could really feel the pressure,” said Francesco Calvaruso, the production manager of Advent, which needed two months to grow, filter and purify a trial vaccine known as AZD1222.
